Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

BACKGROUND: Detection of circulating ESR1 mutations is associated with acquired resistance to aromatase inhibitor (AI) in metastatic breast cancer. Until now, the presence of circulating ESR1 mutations at the end of adjuvant treatment by AI in early breast cancer had never been clearly established....

Descripción completa

Detalles Bibliográficos
Autores principales: Allouchery, Violette, Beaussire, Ludivine, Perdrix, Anne, Sefrioui, David, Augusto, Laetitia, Guillemet, Cécile, Sarafan-Vasseur, Nasrin, Di Fiore, Frédéric, Clatot, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956618/
https://www.ncbi.nlm.nih.gov/pubmed/29769099
http://dx.doi.org/10.1186/s13058-018-0968-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956618/
https://www.ncbi.nlm.nih.gov/pubmed/29769099
http://dx.doi.org/10.1186/s13058-018-0968-0

Ejemplares similares